rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Surrozen, Inc.

SRZN · Nasdaq

Health CareBiotechnologySetting up

SRZN stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 16 weeks. It is 0.2% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Setting up
Weeks in an uptrend
out for 16
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$24.3M
Insider sales, 12 months
$14.5M
Officials’ trades on record
0
Institutions holding
68 (+14)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$12.9M$0$11.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months43
Sale orders, 12 months7
Buyers · sellers7 · 5
WhoDidSharesTraded
Tcg Crossover Gp Ii, Llc10% ownersold162,500at $21.2522 Jul 2026filed 24 Jul 2026
Tcg Crossover Gp Ii, Llc10% ownersold162,500at $21.2522 Jul 2026filed 24 Jul 2026
Craig C. ParkerChief Executive Officersold4,524at $33.334 May 2026filed 5 May 2026
Charles O. WilliamsChief Operating Officersold2,036at $33.334 May 2026filed 5 May 2026
Yang LiExec. Vice President, Researchsold1,584at $33.334 May 2026filed 5 May 2026
Tcg Crossover Gp Ii, Llc10% ownerbought53,329at $24.6924 Mar 2026filed 25 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought53,329at $24.6924 Mar 2026filed 25 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought7,612at $24.9023 Mar 2026filed 25 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought7,611at $24.9023 Mar 2026filed 25 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought595at $24.9916 Mar 2026filed 16 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought595at $24.9916 Mar 2026filed 16 Mar 2026
Tcg Crossover Gp Ii, Llc10% ownerbought17,717at $24.8813 Mar 2026filed 16 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders68+14 on the quarter
New · exited28 · 14
Reported value$269.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TCG Crossover Management, LLCunchanged · filed 14 Aug 20261,473,101$38.2M00.0%
Boxer Capital Management, LLCadded · filed 14 Aug 20261,105,683$27.0M+339,365+44.3%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026683,079$17.7M-48,059−6.6%
Point72 Asset Management, L.P.new · filed 14 Aug 2026664,272$17.2M+664,272
Venrock Adviser, LLCunchanged · filed 14 Aug 2026632,931$16.4M00.0%
STEMPOINT CAPITAL LPadded · filed 14 Aug 2026602,798$13.8M+406,817+207.6%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026503,985$13.1M+274,592+119.7%
Spruce Street Capital LPunchanged · filed 13 Aug 2026432,040$11.2M00.0%
BlackRock, Inc.added · filed 7 Aug 2026394,864$10.2M+367,013+1317.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026392,550$10.2M+223,458+132.2%
31 Dec 2023 – 30 Jun 2026
164166Dec 23Sep 24Mar 25Dec 25Jun 26

Everyone who traded it

Chen-Ming Yu Company insider10% owner · last 22 Jul 20260 · 1
TCG Crossover GP II, LLC Company insider10% owner · last 22 Jul 202610 · 1
Andrew Pedrum Maleki Company insiderChief Financial Officer · last 15 Jun 20260 · 0
Charles O. Williams Company insiderChief Operating Officer · last 15 Jun 20261 · 3
Craig C. Parker Company insiderChief Executive Officer · last 15 Jun 20261 · 1
Yang Li Company insiderExec. Vice President, Research · last 15 Jun 20260 · 3
Anna Berkenblit Company insiderDirector · last 13 May 20260 · 0
Christopher Y. Chai Company insiderDirector · last 13 May 20260 · 0
David J. Woodhouse Company insiderDirector · last 13 May 20260 · 0
Eric Bjerkholt Company insiderDirector · last 13 May 20260 · 0
Mace Rothenberg Company insiderDirector · last 13 May 20260 · 0
Mary Haak-Frendscho Company insiderDirector · last 13 May 20260 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Free cash flow marginFY 2025 · to 31 Dec 2025-874%
Return on capital employedFY 2025 · to 31 Dec 2025-47.4%
Share count trendFY 2025 · to 19 Mar 202617.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$89.2M
Free cash flowFY 2025 · to 31 Dec 2025−$30.4M

Analyst forecasts

No analyst forecasts yet.